Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i> BRAF <sup>V600E</sup> </i> -Mutated Anaplastic Thyroid Carcinoma
Jennifer Wang(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Renata Ferrarotto(The University of Texas MD Anderson Cancer Center), Priyanka Iyer(The University of Texas MD Anderson Cancer Center), Mark Zafereo(The University of Texas MD Anderson Cancer Center), Maria Gule-Monroe(The University of Texas MD Anderson Cancer Center), David I. Rosenthal(The University of Texas MD Anderson Cancer Center), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Clifton D. Fuller(The University of Texas MD Anderson Cancer Center), Neil D. Gross(The University of Texas MD Anderson Cancer Center), Michelle D. Williams(The University of Texas MD Anderson Cancer Center), Ryan P. Goepfert(The University of Texas MD Anderson Cancer Center), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Stephen Y. Lai(The University of Texas MD Anderson Cancer Center), Salmaan Ahmed(The University of Texas MD Anderson Cancer Center), Charles Lu(The University of Texas MD Anderson Cancer Center), Jack Phan(The University of Texas MD Anderson Cancer Center), Erich M. Sturgis(Baylor College of Medicine), William H. Morrison(The University of Texas MD Anderson Cancer Center)
Cited by 229
Related Papers
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|507